Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute Leukemia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05477667

Enrollment

100

Registered

2022-07-28

Start date

2022-10-01

Completion date

2023-04-30

Last updated

2022-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Hodgkin Lymphoma and Acute Leukemia

Brief summary

MiRNAs are noncoding RNAs (ncRNAs) that drive post-transcriptional negative regulation of gene expression by promoting the degradation or translational blockade of their target mRNAs. MiRNAs are 21-24-nucleotide-long RNA molecules that are processed from longer RNA precursors (pri-miRNAs) , and either the 5' or the 3' strand of the mature miRNA duplex is loaded into the Argonaute (AGO) family of proteins to form a miRNA-induced silencing complex (miRISC) When bound to AGO proteins, mature miRNAs destabilize or inhibit the translation of partially complementary target mRNAsMiRNA-124 has been shown to be a tumor suppressor, and a decrease in its expression level is typical of tumors of various localization, but there is no evidence of the role of miRNA-124 in the development of NHL . There are a number of studies reflecting the involvement of miRNA-124 in hematopoiesis. Liu et al. showed that miRNA-124 regulates Tip110 that is involved in the differentiation of hematopoietic stem cellsThe let-7 family has been shown to influence the pathogenesis of a variety of hematological malignancies through the changing expression of a number of oncogenic pathways, particularly those related with MYC and that might affect hematopoietic carcinogenesis through the modulation of inflammatory pathways

Interventions

DIAGNOSTIC_TESTreal time pcr

Detection of expressin level of MiRNA-124 and let-7a using real time pcr

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 80 Years

Healthy volunteers

Inclusion criteria

* approval to sign an informed written consent, * patient with NHL and acute leukemia .

Exclusion criteria

* Refusal to sign an informed written consent, * patient on chemotherapy

Design outcomes

Primary

Measure	Time frame	Description
MiRNA-124 level	6 months	Detection of expressin level of MiRNA-124 IN Non-Hodgkin's Lymphoma and acute leukemia
let-7a level	6 months	Detection of expressin level of let-7a IN Non-Hodgkin's Lymphoma and acute leukemia

Countries

Egypt

Contacts

Primary Contactsara t mahmoud, assisstent professor

sara.ahmed@med.sohag.edu.eg01024914157

Backup Contactrania M bakry, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026